SEC Form 4 · accession 0001209191-15-048133
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William D Schwieterman
Officer — President and CEO · Director
Period of report
May 28, 2015
Accepted (ET)
May 29, 2015 · 9:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000908259
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $1.43 | May 28, 2015 | A | 75,000 | A | — | May 28, 2025 | Common Stock | 75,000 | 75,000 | D |
| Employee Stock Option (Right to Buy)F1,F3 | $1.43 | May 28, 2015 | A | 300,000 | A | — | May 28, 2025 | Common Stock | 300,000 | 300,000 | D |
Explanation of responses
- F1Dr. Schwieterman was awarded options to purchase OXiGENE, Inc. common stock, $0.01 par value per share (the "Stock Options") pursuant to the OXiGENE, Inc. 2015 Equity Incentive Plan in connection with his service as President and Chief Executive Officer.
- F2The Stock Options will vest upon the occurrence of a change of control (as such term is defined in Dr. Schwieterman's Employment Agreement with OXiGENE, Inc., dated May 12, 2015) and the value of OXiGENE, Inc.'s common stock in connection with such change of control is at least $15.00 per share, as adjusted for stock splits, if any.
- F325% of the Stock Options will vest on the first anniversary of the date of grant and the remainder will vest in 36 substantially equal monthly installments beginning one year and one month after the grant date.